A Phase 1 Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of TTHX1114(NM141) Ophthalmic Solution In Healthy Adult Volunteers
Latest Information Update: 21 Apr 2023
At a glance
- Drugs TTHX 1114 (Primary)
- Indications Corneal disorders; Corneal ulcer; Fuchs' endothelial dystrophy
- Focus Adverse reactions
- Sponsors Trefoil Therapeutics
Most Recent Events
- 17 Apr 2023 Status changed from recruiting to completed, according to a Trefoil Therapeutics media release.
- 14 Apr 2023 Status changed from recruiting to completed
- 18 Jan 2023 Status changed from planning to recruiting, according to an Trefoil Therapeutics Media release.